IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis.
Nikhil VergisV PatelK BogdanowiczJ Czyzewska-KhanF FiorentinoE DayM CrossN FosterE LordR GoldinE ForrestM ThurszPublished in: Trials (2021)
EudraCT 2017-003724-79 . Prospectively registered on 13 April 2018.